US20180221129A1 - Medical implant based on nanocellulose - Google Patents

Medical implant based on nanocellulose Download PDF

Info

Publication number
US20180221129A1
US20180221129A1 US15/749,563 US201615749563A US2018221129A1 US 20180221129 A1 US20180221129 A1 US 20180221129A1 US 201615749563 A US201615749563 A US 201615749563A US 2018221129 A1 US2018221129 A1 US 2018221129A1
Authority
US
United States
Prior art keywords
microbial cellulose
tube
stent
medical implant
template
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/749,563
Other languages
English (en)
Inventor
Falk RAUCHFUSS
Utz Settmacher
Dieter Klemm
Wolfgang Fried
Thomas Richter
Katrin Petzold-Welcke
Carola RUHE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaetsklinikum Jena
Original Assignee
KKF UG
Universitaetsklinikum Jena
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KKF UG, Universitaetsklinikum Jena filed Critical KKF UG
Publication of US20180221129A1 publication Critical patent/US20180221129A1/en
Assigned to KKF UG, Universitätsklinikum Jena reassignment KKF UG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: Ruhe, Carola, FRIED, WOLFGANG, RICHTER, THOMAS, KLEMM, DIETER, PETZOLD-WELCKE, KATRIN, SETTMACHER, UTZ, Rauchfuß, Falk
Assigned to Universitätsklinikum Jena reassignment Universitätsklinikum Jena ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KKF UG, Universitätsklinikum Jena
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/005—Ingredients of undetermined constitution or reaction products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/146—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2002/041—Bile ducts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/04—Hollow or tubular parts of organs, e.g. bladders, tracheae, bronchi or bile ducts
    • A61F2002/044—Oesophagi or esophagi or gullets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001—Designing or manufacturing processes
    • A61F2240/002—Designing or making customized prostheses
    • A61F2240/004—Using a positive or negative model, e.g. moulds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2240/00—Manufacturing or designing of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2240/001—Designing or manufacturing processes
    • A61F2240/005—Templates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2420/00—Materials or methods for coatings medical devices
    • A61L2420/08—Coatings comprising two or more layers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/22—Materials or treatment for tissue regeneration for reconstruction of hollow organs, e.g. bladder, esophagus, urether, uterus
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L1/00—Compositions of cellulose, modified cellulose or cellulose derivatives
    • C08L1/02—Cellulose; Modified cellulose

Definitions

  • the present invention relates to a medical implant, particularly for repairing a bile duct, and a method for producing such implant.
  • a reconstruction of the biliary duct is often a critical issue since loss of biliary duct substance often forces the surgeon to high-risk operations or to operations like bilioenteric anastomosis. Such loss of substance, or lesions, may happen when gall bladder is removed and the common bile duct is incidentally injured or when damages are caused by ischemia, e.g. after liver transplantation or tumor resection.
  • bilioenteric anastomosis is a connection between common bile duct and parts of the gastrointestinal tract.
  • an intestinal loop is connected to the common bile duct.
  • sphincter mechanism is bypassed, which is the natural barrier between biliary system and intestinal lumen. This often results in migration of intestinal bacteria in the bile duct, which can lead to an infection of the biliary system.
  • Particularly patients after a liver transplantation are affected by this problem and endangered due to their immunosuppressed state.
  • Attemtps to eliminate a bile duct defect are known from only a few scientific groups.
  • Aikawa et al (2012) describe a bile duct replacement by implantation of a polymeric tube that could be resorbed.
  • a histologic evidence of a completely regenerated bile duct could be made no earlier than after four months, which is a too long time for a successful application in human body.
  • an autologous segment of a vein (external jugular vein) was implanted and stabilized with an absorbable or resorbable stent. With this method, it took even six months for creating a new bile duct. Moreover, not every patient possesses suitable veins and a further surgical intervention is necessary in order to obtain the necessary vein segment.
  • the present invention is based on the problem of providing an improved medical implant, particularly for repairing a defect in a bile duct. Particularly, it was an object to provide a material for bile, bile duct and liver surgery that is able to fulfil one or more of the following tasks:
  • the present invention provides with a medical implant and a method for producing such implant as stated in the independent claims.
  • the present invention particularly provides with a medical Implant, comprising
  • the microbial cellulose tube surrounds the stent.
  • an outer surface of the stent contacts the inner surface of the microbial cellulose tube.
  • the microbial cellulose tube is placed on the outer surface of the stent.
  • the medical implant of the invention is preferably used as a temporary medical implant which can be completely or partially removed after having fulfilled its function.
  • partial removal the stent is removed from the body.
  • the tube is removed.
  • the tube and the stent can be removed via an endoscopic approach.
  • the regenerated bile duct was stable. Thus, all or nearly all “foreign material” will be removed out of the biliary system.
  • the microbial cellulose tube is not the intended replacement for a bile duct.
  • the microbial cellulose tube is a support for growth of a new bile duct, or bile duct segment from body's own tissue.
  • the implant of the invention is particularly suitable for generating a new bile duct from body's own tissue, or for repairing a bile duct by generating a new bile duct section from body's own tissue between two already existing bile duct ends.
  • body tissue grows/has been grown on the surface of the microbial cellulose tube and so, a bile duct can be created or repaired.
  • the stent is introduced into the microbial cellulose tube (also abbreviated as “tube”), i.e. into the interior, also called the cavity, of the tube.
  • the stent keeps open the interior, or the lumen, of the tube and prevents a closure of the tube.
  • a stent can lead to expansion of the tube, as described below, and thereby improve the functionality of the implant.
  • the stent is slit into the microbial cellulose tube.
  • the microbial cellulose tube surrounds the stent.
  • the stent is a tubular stent.
  • the term tubular stent also comprises stents having one or more openings on the surface or the jacket of the tube.
  • the tubular stent can comprise a tube made of a mesh structure or a tube with closed jacket.
  • the outer diameter of the stent may be the same, smaller, or higher, particularly slightly higher, than the inner diameter of the microbial cellulose tube. If the outer diameter of the stent is higher, the tube is expanded.
  • the implant may comprise an expanded microbial cellulose tube, preferably expanded in radial direction. Expansion means an expansion in comparison to a tube that is not combined with the stent.
  • the inner diameter of the cellulose tube is the inner diameter of the tube before it is combined with the stent.
  • a stent is a hollow device placed in the body and may be used to create a passage between two hollow spaces or for keeping open a hollow organ or a vessel.
  • the stent is used as stiff support for the microbial cellulose tube. In this sense, the stent is used for keeping open the microbial cellulose tube.
  • the stent can also keep open parts of an existing duct in the body, for example parts of a bile duct.
  • the stent is preferably a billiary stent.
  • the stent may be made of polymer, particularly it can be a polymer tube.
  • the stent may comprise openings on its outer surface. Such openings can be openings that are present in addition to openings at both ends of a stent.
  • the stent can be over its whole length placed inside of the tube of microbial cellulose or over a part of its length placed inside of the tube.
  • the stent protrudes from the microbial cellulose tube at one end (a first end) of the microbial cellulose tube and an opposite end (a second end) of the microbial cellulose tube.
  • a protrusion has the advantage that protruding ends of the stent can be inserted each into the bile duct, for example, when between two bile duct segments new tissue shall be generated in order to connect the segments.
  • a protrusion means a protrusion in longitudinal direction, i.e. in direction of the longitudinal axis (L) of the tube.
  • insertion of the implant can comprise following steps:
  • body tissue can grow over the tube until the bile duct segments are re-connected. Then, the implant can be removed.
  • the outer layer of the BNC tube in the implant is subjected to pressure or strain, which can for example be done by expanding the BNC tube with a stent. It has been shown that by such measure, meshes are narrowed and a structure of BNC fibers in the outer layer is subjected to compaction.
  • a stent with an outer diameter larger than the inner diameter of the tube can be used, to reach this result.
  • the inner diameter of the tube is the inner diameter of the tube before it is combined with the stent.
  • the implant of the invention may comprise an expanded microbial cellulose tube, preferably in radial direction.
  • expanded means an expansion in comparison to a tube that is not combined with a stent, for example a tube after its production and optional storage in suitable liquid medium, such as deionized water.
  • the microbial cellulose tube is expanded by the stent in radial direction.
  • An expansion in radial direction means that at least the inner diameter of the tube is increased, and preferably that the inner and the outer diameter of the tube are increased.
  • the expansion can be in one or more radial directions.
  • the tube can be expanded in at least one radial direction, preferably in more radial directions, even more preferably in a multitude of radial directions or even each radial direction.
  • the diameter can be increased in at least one radial direction, preferably in more radial directions, even more preferably in a multitude of radial directions or even each radial direction.
  • the tube can be symmetrically or asymmetrically expanded, in relation to its longitudinal axis, or in relation to a distinct position or point at the longitudinal axis.
  • the tube can be expanded in radial direction at one or more positions along the longitudinal axis of the tube, preferably a multitude of positions. Most preferably, the tube is radially expanded over most of its length or its whole length.
  • the tube and the stent may be linear or curved, or have one or more bends.
  • a linear tube is also called hollow cylinder.
  • microorganism means a cellulose which is produced by a microorganism.
  • exemplary microorganisms are fungi, bacteria and algae.
  • a number of microorganisms is able to produce microbial cellulose. These include, but are not limited to, algae such as Valonia and Boergesenia , fungi such as Dictyostelium discoideum and bacteria such as Gluconacetobacter ( Komagataeibacter ), Enterobacter, Agrobacterium, Sarcina, Pseudomonas, Rhizobium and Zoogloea .
  • Acetobacter xylinum Gluconacetobacter, Acetobacter pasturianus, Acetobacter aceti, Acetobacter ransens .
  • a particularly useful microorganism is Gluconacetobacter , particularly Gluconacetobacter xylinus.
  • the layers of microbial cellulose in the tube are preferably made of a network of fibers.
  • Microbial cellulose may be produced by microorganisms at the interface between air and a nutrient medium in the form of a biofilm (fleece).
  • the bacteria produce the cellulose in form of fibrils. These self-assemble into fibers. Through the interweaving of the fibers, a three-dimensional, highly hydrous nanofiber network of approximately 99% water and 1% cellulose is created (Jonas R, Farah L F: Production and application of microbial cellulose., Polym. Degrad. Staff (1998), 59 (1-3), 101-106; A Hirai, Horii F: Cellulose Assemblies produced by Acetobacter xylinum.
  • Microbial cellulose is, if it is produced by bacteria, also named herein as “bacterial cellulose”, “bacterial nanocellulose” (BNC) or simply “nanocellulose”.
  • bacterial nanocellulose is derived from the fact that bacterially produced cellulose, as mentioned above, forms a nanofiber network.
  • the microbial cellulose tube comprising several layers of microbial cellulose is obtainable by or obtained by a method comprising following steps:
  • the microbial cellulose tube singly or as part of an implant of the invention, can show one or more of features, singly or in any combination:
  • the culture medium also referred to as a “broth” or “broth” may contain conventional ingredients for culturing a cellulose producing microorganism such as glucose, peptone, yeast extract, sodium hydrogen phosphate and citric acid in aqueous solution (Hestrin Schramm medium).
  • An alternative acidic medium consists of an aqueous solution of glucose, peptone, yeast, acetic acid and ethanol.
  • the method is preferably carried out at a temperature of 20 to 40° C.
  • the method for producing the tube cultivation is carried out not purely static.
  • the template and stock mixture containing culture solution and microorganism are moved relative to each other so that the surface of the template is wetted. A permanent contact of the template with the mixture stock is excluded.
  • the template and the mixture reservoir, having the culture medium and the microorganism can be moved relative to each other, thereby temporarily, but not permanently brought into contact.
  • Feature of the method is a template that is periodically, but not permanently, brought into contact with culture solution and microorganism, the formation of a film containing the culture medium and the microorganism on the template and the biosynthesis of cellulose in the template only in and/or on the film—outside of the stock mixture.
  • interrupting contact means that the contact between the template and mixture stock is so interrupting that no part of the surface of the template during the interruption has contact with the mixture stock.
  • the shape of the interior, or the inner contour, of the tube is defined by a suitably shaped template, on whose surface in carrying out the method, a liquid film is formed, in which the biosynthesis of cellulose happens.
  • the cellulose produced directly on the template surface later forms the inner surface of the tube.
  • a first layer of cellulose is formed on the template.
  • Further layers are formed by steps d), e), f) and their repetition. Steps b) and c) can be a combined step. Steps e) and f) can be a combined step.
  • the outer shaping of the hollow body according to the invention is carried out without contact, only through the influence of gravity.
  • the outer shape of the hollow body is defined solely by the choice of culture conditions.
  • the culture conditions include, for example, the direction of the force of gravity, the frequency and spacing of individual turns, the time interval between the wetting time, the residence time, as explained below, the temperature and the cultivation time.
  • the method for producing the tube can be carried out in the apparatus described in WO2013/113675A1.
  • BNC-tubes produced by the method are characterized by improved mechanical properties and bioactive surfaces. So, on a bioactive outer surface body tissue, particulary bile duct epithelium can be generated.
  • Length and internal diameter of the tube are variable and variably combined.
  • Exemplary internal diameters are 1-30 mm, preferably 2-8 mm, and exemplary lengths are 5 to 500 mm, preferably 100-200 mm.
  • the length to diameter ratio is preferably greater than 1.
  • the inner diameter can also vary within a tube.
  • the tube particularly its cavity, may also have a differently shaped cross-section, for example a square, rectangular, triangular or star-shaped cross-section instead of a round.
  • the template is, as already mentioned, the negative mold of the cavity of the tube and the inner wall of the tube.
  • the term “negative mold” refers to the tool, the male mold is the desired result, in this case, the tube/void/tube wall.
  • the template is shaped complementary to the shape of the desired cavity produced and is specified accordingly. Accordingly, the shape of the template is defined by the shape of the above-mentioned hollow body.
  • the template sets the internal geometry of the hollow body.
  • the template is cylindrical, with a diameter of 1-30 mm, preferably 2-8 mm, and a length of 5-500 mm, preferably 100-200 mm.
  • the template may have an arbitrary cross-section, such as round, rectangular, in particular square, rectangular, triangular, or star-shaped or snowflake-shaped.
  • the template has a surface having the structures in the millimeter, micrometer and/or nanometer scale.
  • the structures are, for example, protrusions or depressions or both.
  • the structures may have different geometries.
  • the material from which the surface of the template is made from is in principle not limited.
  • the template has a surface made of wood, metal, such as aluminum, stainless steel or titanium, plastics, ceramics, synthetic polymers such as polypropylene, polyesters, polyamides or Teflon, paper or glass fabric.
  • the template material can be used pure or surface-coated in a proper manner. It can also be the entire template from one of the mentioned substances exist.
  • an arrangement of a plurality of templates is employed in the process, also referred to as template matrix. It can templates with the same or different geometry, in particular different cross-sections, and/or be used of the same or different material. Thereby several identical or different tubes can be obtained in the method.
  • An example of an arrangement of a plurality of templates is an arrangement of a plurality of cylindrical templates for the production of several tubes. Multiple templates of the same or different geometry can be fixed in a jig (template array).
  • the template is periodically, preferably for a short time, wetted with the mixture comprising the culture broth and the microorganism.
  • a liquid film forms on the surface of the template.
  • the shape of this liquid film is determined by the position of the template in the room, because the gravity acts on this film.
  • a liquid film is formed, comprising the liquid culture medium and the microorganism.
  • microbial cellulose is formed on the surface of the template.
  • the liquid film can be distributed on the template by the template is rotated about one or more spatial axes, for example X, Y and/or Z in a Cartesian coordinate system. This is explained in the examples of WO2013/113675A1 by means of the movement device.
  • the distribution of the liquid can be influenced by the type of the predetermined rotational movement of the template, wherein the rotational movement can also be interrupted.
  • the external geometry of the tube is thus determined by a defined distribution of liquid film and by a defined movement under the influence of gravity.
  • the template has a geometry with a length to diameter ratio of greater than 1.
  • the template may have a cylindrical geometry with a length to diameter ratio of greater than 1, for producing a straight tube.
  • the template has a longitudinal axis.
  • the tube is a hollow cylinder with a central axis which runs centrally and longitudinally of the cylinder expansion through the cavity. The process is then preferably carried out so that the template is rotated about one or more axes in space.
  • a liquid film is formed on the surface of the template.
  • the liquid film is formed when the template and the mixture comprising the culture medium and the microorganism are moved relative to each other and are thereby brought into contact.
  • contacting the surface of a template with the mixture is done such that the template is dipped into in the mixture comprising the culture medium and the microorganism. Movement, particularly rotation, of the template in one or more of spatial axes can be superimposed to the immersion an interruption of the contact of the template to mixture.
  • the oxygen-containing atmosphere is preferably air or pure oxygen or an oxygen-containing gas mixture.
  • Microbial cellulose is formed in and/or on the liquid film when it comes into contact with oxygen.
  • the tube, formed of nanocellulose, is separated from the template.
  • the separation takes place for example in that the cellulose formed is stripped from the template, or the template is removed in another manner.
  • the cellulose is stripped from a cylindrical template and the tube is obtained.
  • the template may be rotated, about one or more spatial axes, at least during step c) and/or step f), or one or more of the steps f), when the step f) is carried out several times.
  • the shape and distribution of the liquid film and the shape of the forming product can be influenced.
  • the template is coated with a defined liquid film, which in turn leads to a defined shape of the forming product.
  • the rotation can be done during step a) and b) and/or during the steps d) and e).
  • This sequence of steps d) -f) are repeated one or more times until a desired amount of cellulose is formed on the surface of the template and the cellulose has reached a desired overall layer thickness.
  • the so-called total layer may be composed of several individual layers or phases. A synthesis of other microbial cellulose takes place on already formed cellulose.
  • the times of contacting the surface of a template (step a) with a mixture reservoir and of contacting the microbial cellulose generated in step c) with the mixture stock (step d) are referred to as “wetting time”.
  • the time of contacting of the liquid film with an oxygen-containing atmosphere (steps c and f) are referred to as “residence time”. Wetting times and residence times can be controlled independently of each other.
  • the residence time is in one embodiment, 1-60 minutes, preferably 5-40 min.
  • the total cultivation time is preferably 1-7 days.
  • the total cultivation time corresponds to the total process time within which all steps of the method are performed, such as turning, wetting and other steps.
  • the duration of the procedure determines the thickness of the formed microbial cellulose on the template, which corresponds to the wall thickness of the tube.
  • the tube produced by the method can be cleaned to remove residues and components of the culture medium and microorganisms.
  • water, aqueous acidic or alkaline solution or an organic solvent, or a combination can be used.
  • the tubes obtained with the method can be used without drying after a cleaning and sterilization process for producing an implant of the invention.
  • the tube preferably at least the outer surface or the outer layer of the microbial cellulose tube is porous. Porosity can be reached by producing the tube according to above-described method. Porosity improved formation/generation of tissue on the microbial cellulose.
  • the tube has a wall with an inner surface and an outer surface, wherein the inner surface and outer surface have an identical or similar cover by fibers of microbial cellulose per unit area.
  • BNC form fibers of more or less dense and more or less porous networks.
  • the coverage per unit area can then be expressed as
  • the coverage can be expressed as a percentage.
  • similar in this context means that coverage the inner surface and the outer surface differ relative to one another by a maximum of 20%, preferably at most 10%, most preferably at most 5%.
  • a similar coverage as defined above represents a similar porosity of the inner and outer surface, wherein the porosity with respect to a surface is two-dimensionally defined as
  • porosity (two-dimensional) Part of the observed area section not covered with fibers/total area of the area section.
  • the area not covered with fibers may be referred to as “open-pore surface” or “surface pores”.
  • BNC fibers can be taken into account, which are just outside of the assumed two-dimensional inner/outer surface.
  • an electron micrograph a two-dimensional representation of the outer or inner surface of the wall of the hollow body is obtained.
  • the pictured BNC fibers are not always but in a plane, because the surfaces can exhibit a certain roughness and/or optionally BNC fibers imaged are lying out of sight of the viewer behind the surface. It has been found that in the hollow body according to the invention the outer surface of the wall may be rougher than the inner surface.
  • all BNC fibers are also taken into account that on a scanning electron micrograph (10,000 times magnification) are visible and they are treated as if they were in a plane, since the coverage/porosity is based on a on a unit area.
  • the tube has a wall with an inner surface and an outer surface, the inner surface and the outer surface having a similar porosity, as defined above.
  • similar means with respect to the porosity, that the two-dimensional porosity of the inner surface and the outer surface differ relative to one another by a maximum of 20%, preferably at most 10%, most preferably at most 5%.
  • the tube has a wall with an inner surface and an outer surface, wherein the wall comprises multiple layers of microbial cellulose, which run parallel to the inner and outer surface of the wall. These layers are hereinafter also referred to as “phases”. The layers correspond to the above “single layers or phases” of the wall of the hollow body.
  • the phases are in their density over the entire thickness homogeneous, i.e. they have no density gradient.
  • the phases are preferably characterized by a uniform (isotropic), well-branched fiber network. Number and strength of the phases are controlled adjustable.
  • phase do not have to be obtained by one single process cycle of wetting/filming and subsequent cellulose formation in or on the film.
  • a phase can be formed by several such cycles.
  • the phases are visually distinguishable from each other by scanning electron microscopy, for example, at 24 ⁇ magnification.
  • the phases are made up of a network of fibers bacterial Nanocellulose, wherein the fiber structures of the phases in the comparison of the phases may be the same or different.
  • the invention also describes a tube whose wall is made of layers, also referred as phases as described above, wherein one of the layers comprises the inner surface, i.e. the cavity side surface, and a further layer comprises the outer surface, wherein these two layers have an identical or similar porosity.
  • the layer/phase comprising the inner surface of the wall is also referred to as the “lumen-side layer/phase” or “cavity-side layer/phase”.
  • the layer/phase comprising the outer surface of the wall is also referred to as “outer-side layer/phase”.
  • the porosity is spatially defined as:
  • the volume of the entire layer/phase may be used. But it is also possible to look at just a fraction of the volume of the layer/phase and look at this volume part to the purpose of measuring the porosity as “total”.
  • similar means with respect to the spatial porosity that the porosity of the lumen-side phase, and the porosity of the outside phase vary relative to each other by at most 20%, preferably at most 10%, most preferably at most 5%.
  • An identical or similar three-dimensional porosity means that the lumen-side layer/phase and the outside layer/phase have an identical or similar density.
  • Identical or similar three-dimensional porosity, as defined above, means that the lumen-side layer/phase and the outside layer/phase have an identical or similar fiber density.
  • the density is preferably given as mass/volume and the fiber density is specified as a number of fibers/volume.
  • volume the volume of the entire layer/phase may be used.
  • the term “similar” means with respect to the density and fiber density that the density/fiber density of the lumen-side phase and the density/fiber density of the outside phase relative to each other differ by not more than 20%, preferably at most 10%, most preferably 5% in maximum.
  • one or more other phases are disposed between the lumen-side phase and the outside phase.
  • these one or more further phases have an identical or similar porosity, density, and fiber density as that of the lumen-side phase and the outside phase.
  • the invention is directed to a process for producing a medical implant, comprising:
  • any implant as described before can be produced.
  • the method step of producing a microbial cellulose tube, comprising sub-steps a)-g) have been described before.
  • Introducing a stent into the tube can be done by sliding the stent into the interior/cavity of the tube.
  • the implant of the invention can be used for surgery or a method of surgery.
  • the implant can be used for surgery of gall bladder, hepatobiliary malignancy surgery, bile duct and/or liver, e.g. gall removal or liver transplantation.
  • the implant can particularly be used for repairing or regeneration of bile duct. Further fields of use are the use as esophagus implant or urether implant, particularly in case of esophagus or urether lesion.
  • the present invention is also related to a medical implant as described herein, for use in surgery, or in a method of surgery, of gall bladder, hepatobiliary malignancy surgery, bile duct, esophagus, urether or liver.
  • the present invention is also related to a medical implant as described herein, for use in repairing or regeneration, or in a method of repairing or regeneration, of a bile duct, an esophagus lesion or an urether lesion.
  • FIG. 1 BNC tube on a template, in a cross section
  • FIG. 2 A medical implant of the invention
  • FIG. 3 A medical implant of the invention which is inserted into an animal's body in order to regenerate a bile duct
  • a device and reactor as shown and described in FIG. 1 of WO2013/113675A1 is used for preparation of a BNC tube.
  • To prepare the products several rod shaped templates are arranged in a clamping and inserted into the moving means of the device.
  • the reactor is then closed and sterilized. After sterilization of the entire reactor the reservoir of the reactor is filled under sterile conditions with a mixture of cellulose producing microorganisms and separately sterilized culture solution filled.
  • each BNC tube on the template has assumed a desired shape a desired wall thickness of about 1-3 mm.
  • the length and inner diameter of each BNC tube is determined by the dimensions of the corresponding rod-shaped template.
  • the tubes are stripped from the templates, purified and stored wet, preferably in deionized water.
  • the BNC tube had a length of approximately 80-150 mm, an inner diameter of approximately 2-4 mm and an outer diameter of approximately 4-10 mm.
  • the number of distinct BNC layers in the tube is about 5-7.
  • the BNC tube 1 is placed onto the template 8 , which is a metal rod.
  • L is the longitudinal axis of the BNC tube 1 .
  • L extends in the viewing direction.
  • the BNC tube 1 is composed of three layers 5 , 6 , 7 , wherein layer 5 is an inner layer, 6 a middle layer and 7 the outer layer. More than the shown layer 6 between the outer layer 7 and the inner layer 5 can be present.
  • the layers 5 , 6 , 7 are concentric or substantially concentric to a longitudinal axis (L) of the tube 1 .
  • the inner surface of the lumen of the BNC tube 1 is designated as 3 , and the outer surface is 4 .
  • the layers 5 , 6 , 7 of microbial cellulose are made of fibers. Exemplary structures are shown in FIGS. 4, 5, and 6 of WO2013/113675A1.
  • a biliary stent 8 , 5 Fr Biliary Drainage Tube Set/Olympus, Tokyo, Japan
  • a length of 50-120 mm, a diameter of 8.5 Fr was slit into the tube until the stent protruded both ends of the BNC tube in symmetrical manner.
  • the obtained implant 100 is shown in appended FIG. 2 .
  • the microbial cellulose tube 1 comprises a wall 2 with the inner surface 3 and the outer surface 4 .
  • the wall 2 is composed of the BNC layers 5 , 6 , 7 that are shown in FIG. 1 .
  • the tubular stent 9 is placed inside of the microbial cellulose tube 1 .
  • the outer surface 10 of the stent contacts the inner surface 3 of the microbial cellulose tube 1 .
  • the length l 2 of the stent 9 is longer than the length l 1 of the BNC tube 1 .
  • the tubular stent 9 protrudes from the microbial cellulose tube at a first end 11 of the microbial cellulose tube 1 and a second end 12 of the microbial cellulose tube 1 .
  • the outer diameter of the stent 9 may be higher than the inner diameter of the BNC tube 1 (without stent 9 ).
  • the tube 1 is expanded in radial direction. Exemplary directions of expansion are designated with arrows R. It is to be understood that expansion will in this example occur also in other radial directions, since the stent 9 and the tube 1 are circular. A more or less symmetric expansion occurs, thereby increasing the inner diameter of the tube 1 .
  • FIG. 2 shows the implant 100 in a pig in a schematic view. Reference signs correspond to reference signs in FIG. 2 , as far as the implant 100 is concerned.
  • FIG. 3 shows a part of a pig's liver 13 with a first bile duct section, or bile duct end, 14 and a part of the duodenum 15 with a second bile duct section, or bile duct end, 16 .
  • first bile duct section 14 a first protruding part of the stent 9 was introduced.
  • second bile duct section 16 a second protruding part of the stent 9 was introduced.
  • the BNC tube 1 is placed between the bile duct sections 14 , 16 .
  • a connection between the BNC tube 1 and the bile duct sections 14 , 16 is made by sutures 17 , 18 .
  • the BNC tube was still placed in the bile duct, i.e. between the bile duct sections 14 , 16 but was not grown together with the bile duct sections 14 , 16 .
  • New bile duct epithelium was continuously formed on the surface 4 of the BNC tube, as shown by histologic analysis.
  • the bile duct sections 14 , 16 were connected by new bile duct epithelium.
  • the anastomosis was sufficient, in a sense that an anastomosis ring could be observed. No badly healed or insufficient anastomosis were observed. The actual anastomosis was not existent any more since the interponate, i.e. the BNC tube, was repelled.
  • the implant 100 i.e. the BNC tube 1 and the stent 4 could be removed from the bile duct sections 14 , 16 and the newly created bile duct epithelium.
  • the stent 9 was removed through the duodenum 15 . Thereby, the BNC tube 1 was also removed.
  • the BNC tube 1 disassociated from the new bile duct epithelium which was grown on its surface.

Landscapes

  • Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Surgery (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US15/749,563 2015-08-05 2016-08-03 Medical implant based on nanocellulose Abandoned US20180221129A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15179884.0A EP3127561A1 (fr) 2015-08-05 2015-08-05 Implant médical basé sur une nanocellulose
EP15179884.0 2015-08-05
PCT/EP2016/068580 WO2017021468A1 (fr) 2015-08-05 2016-08-03 Implant médical à base de nanocellulose

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/068580 A-371-Of-International WO2017021468A1 (fr) 2015-08-05 2016-08-03 Implant médical à base de nanocellulose

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US17/526,521 Division US11857405B2 (en) 2015-08-05 2021-11-15 Medical implant based on nanocellulose

Publications (1)

Publication Number Publication Date
US20180221129A1 true US20180221129A1 (en) 2018-08-09

Family

ID=53835299

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/749,563 Abandoned US20180221129A1 (en) 2015-08-05 2016-08-03 Medical implant based on nanocellulose
US17/526,521 Active US11857405B2 (en) 2015-08-05 2021-11-15 Medical implant based on nanocellulose

Family Applications After (1)

Application Number Title Priority Date Filing Date
US17/526,521 Active US11857405B2 (en) 2015-08-05 2021-11-15 Medical implant based on nanocellulose

Country Status (10)

Country Link
US (2) US20180221129A1 (fr)
EP (2) EP3127561A1 (fr)
JP (1) JP6858177B2 (fr)
KR (1) KR102564845B1 (fr)
CN (1) CN108289978B (fr)
CA (1) CA2993374C (fr)
ES (1) ES2763455T3 (fr)
HR (1) HRP20192312T1 (fr)
SI (1) SI3331583T1 (fr)
WO (1) WO2017021468A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112515825A (zh) * 2020-12-16 2021-03-19 中南大学湘雅二医院 一种肝胆胰外科用3d打印免缝合胆肠吻合支架
CN115944786A (zh) * 2023-01-09 2023-04-11 华东交通大学 一种一体化双层小血管移植物及制备方法
WO2023089010A1 (fr) * 2021-11-17 2023-05-25 Biotronik Ag Nanocellulose bactérienne et son procédé de fabrication

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107638230B (zh) * 2017-11-08 2020-07-03 管生 一种新型分体式颅内覆膜支架系统及其使用方法
CN108753868A (zh) * 2018-06-08 2018-11-06 东华大学 一种管状细菌纳米纤维素材料及其制备方法和应用
CN109880140B (zh) * 2019-01-30 2022-09-27 东华大学 一种碱缩细菌纳米纤维素管及其制备方法和应用
WO2023174791A1 (fr) * 2022-03-16 2023-09-21 Biotronik Se & Co. Kg Implant médical et son procédé de fabrication

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0396344A3 (fr) * 1989-04-28 1991-04-03 Ajinomoto Co., Inc. Cellulose microbienne creuse, procédé de préparation et vaisseau sanguin artificiel formé à partir de cette cellulose
US5609629A (en) * 1995-06-07 1997-03-11 Med Institute, Inc. Coated implantable medical device
US20030013163A1 (en) * 2000-02-17 2003-01-16 Dieter Klemm Method and device for producing shaped microbial cellulose for use as a biomaterial, especially for microsurgery
DE60115235T2 (de) * 2000-04-28 2006-08-10 Children's Medical Center Corp., Boston Aus gewebe aufgebauter stent
WO2003050266A2 (fr) * 2001-12-11 2003-06-19 Cytograft Tissue Engineering, Inc. Feuillets cellulaires traites par genie tissulaire, leurs procedes de fabrication et leur utilisation
BR0205047C1 (pt) * 2002-11-21 2003-11-04 Ronaldo Da Rocha Loures Bueno Endoprótese revestida com membrana de celulose biossintética
CN101474424B (zh) * 2009-01-16 2013-01-02 中国人民解放军第四军医大学 高仿真组织工程神经修复材料ngcs及其制备方法
CN101584882B (zh) * 2009-06-10 2012-07-25 海南椰国食品有限公司 一种组织工程血管支架材料及其生产方法
CN101921700B (zh) * 2010-09-02 2015-03-11 东华大学 一种制备中空异形细菌纤维素材料的装置及方法
AU2012203620B9 (en) * 2011-06-24 2014-10-02 Cook Medical Technologies Llc Helical Stent
AU2012318307A1 (en) * 2011-10-06 2014-05-15 Purdue Research Foundation System and stent for repairing endovascular defects and methods of use
CA3226017A1 (fr) 2011-10-14 2013-04-18 Humacyte, Inc. Protheses tubulaires
WO2013113675A1 (fr) 2012-01-30 2013-08-08 Kkf Ug Procédé de production de corps creux en cellulose microbienne
BR112016006071B1 (pt) * 2013-09-19 2021-12-28 Universitãtsspital Basel Enxerto vascular artificial e método para a produção de um enxerto vascular artificial
EP3223873B1 (fr) * 2014-11-24 2020-04-08 Biotronik AG Structure d'étanchéité pour implants de valve cardiaque

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112515825A (zh) * 2020-12-16 2021-03-19 中南大学湘雅二医院 一种肝胆胰外科用3d打印免缝合胆肠吻合支架
WO2023089010A1 (fr) * 2021-11-17 2023-05-25 Biotronik Ag Nanocellulose bactérienne et son procédé de fabrication
CN115944786A (zh) * 2023-01-09 2023-04-11 华东交通大学 一种一体化双层小血管移植物及制备方法

Also Published As

Publication number Publication date
SI3331583T1 (sl) 2020-02-28
EP3127561A1 (fr) 2017-02-08
KR102564845B1 (ko) 2023-08-08
ES2763455T3 (es) 2020-05-28
HRP20192312T1 (hr) 2020-03-20
CA2993374C (fr) 2023-09-26
EP3331583B1 (fr) 2019-10-02
EP3331583A1 (fr) 2018-06-13
JP6858177B2 (ja) 2021-04-14
CA2993374A1 (fr) 2017-02-09
EP3331583B8 (fr) 2019-12-04
US11857405B2 (en) 2024-01-02
WO2017021468A1 (fr) 2017-02-09
JP2018525095A (ja) 2018-09-06
CN108289978A (zh) 2018-07-17
US20220071758A1 (en) 2022-03-10
CN108289978B (zh) 2021-10-01
KR20180074663A (ko) 2018-07-03

Similar Documents

Publication Publication Date Title
US11857405B2 (en) Medical implant based on nanocellulose
AU2016366783B2 (en) Methods of producing biosynthetic bacterial cellulose membranes
Kowalska-Ludwicka et al. Special paper–new methods modified bacterial cellulose tubes for regeneration of damaged peripheral nerves
CN109701080B (zh) 一种4轴3d打印管状医用支架及其制备方法
US20220257831A1 (en) Method and device for in vivo bronchus regeneration
US20030013163A1 (en) Method and device for producing shaped microbial cellulose for use as a biomaterial, especially for microsurgery
Bao et al. Implantation of air-dried bacterial nanocellulose conduits in a small-caliber vascular prosthesis rabbit model
CA2400372A1 (fr) Procede et dispositif de production de cellulose microbienne moulee destinee a servir de biomateriau, notamment pour la microchirurgie
US8993324B2 (en) Process and support structure for the cultivation of living cells
JPWO2010087015A1 (ja) 神経再生誘導管
CN102641160A (zh) 一种具有双层复合结构的人工胆管仿生支架及其制备方法
WO2013113675A1 (fr) Procédé de production de corps creux en cellulose microbienne
DE102012201268B4 (de) Verfahren zur Herstellung von Hohlkörpern aus mikrobieller Cellulose
RU2808880C1 (ru) Биорезорбируемый имплантат кровеносных сосудов на основе нановолокон
DE102012201272B4 (de) Vorrichtung zur Herstellung von Hohlkörpern aus mikrobiellem Polymer
JP4626725B2 (ja) 細胞培養用コラーゲン
Klemm et al. Bacterial nanocellulose for medical applications: potential and examples
CN118178054A (zh) 具有层次孔结构的引导骨再生支架与其制备方法和应用
KR20220141274A (ko) 콜라겐 멤브레인을 포함하는 이식물
CN116350855A (zh) 一种胶原纤维定向排列的卷轴型神经导管及其制备方法和应用

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: KKF UG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAUCHFUSS, FALK;SETTMACHER, UTZ;KLEMM, DIETER;AND OTHERS;SIGNING DATES FROM 20180430 TO 20180620;REEL/FRAME:046920/0490

Owner name: UNIVERSITAETSKLINIKUM JENA, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:RAUCHFUSS, FALK;SETTMACHER, UTZ;KLEMM, DIETER;AND OTHERS;SIGNING DATES FROM 20180430 TO 20180620;REEL/FRAME:046920/0490

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: ADVISORY ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

AS Assignment

Owner name: UNIVERSITAETSKLINIKUM JENA, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KKF UG;UNIVERSITAETSKLINIKUM JENA;SIGNING DATES FROM 20200930 TO 20201012;REEL/FRAME:054347/0412

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: FINAL REJECTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION